The estimated Net Worth of David Roth is at least $1.77 Million dollars as of 31 March 2024. David Roth owns over 15,333 units of Syros Pharmaceuticals stock worth over $24,686 and over the last 10 years he sold SYRS stock worth over $136,711. In addition, he makes $1,608,270 as Chief Medical Officer at Syros Pharmaceuticals.
David has made over 7 trades of the Syros Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 10,451 units of SYRS stock worth $51,732 on 3 April 2024.
The largest trade he's ever made was exercising 18,875 units of Syros Pharmaceuticals stock on 31 October 2023 worth over $30,389. On average, David trades about 3,917 units every 22 days since 2015. As of 31 March 2024 he still owns at least 15,333 units of Syros Pharmaceuticals stock.
You can see the complete history of David Roth stock trades at the bottom of the page.
Dr. David A. Roth M.D. serves as Chief Medical Officer of the Company. Previously, Dr. Roth has been our chief medical officer since December 2015. Previously, Dr. Roth was employed by Infinity Pharmaceuticals, Inc., a pharmaceutical company, from September 2013 until September 2015, serving most recently as its executive vice president and chief medical officer and previously as its senior vice president of clinical development and medical affairs. Prior to joining Infinity, Dr. Roth was the vice president, early development in the oncology business unit of Pfizer Inc., a pharmaceutical company, from 2009 to August 2013. Prior to joining the pharmaceutical industry, Dr. Roth’s experience included over ten years in research and clinical practice as an academic hematologist, and he served on the full-time faculty at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston. Dr. Roth received his B.S. from the Massachusetts Institute of Technology and his M.D. from Harvard Medical School in the Harvard MIT Division of Health Sciences and Technology, where he remains on the affiliated faculty.
As the Chief Medical Officer of Syros Pharmaceuticals, the total compensation of David Roth at Syros Pharmaceuticals is $1,608,270. There are 3 executives at Syros Pharmaceuticals getting paid more, with Nancy Simonian having the highest compensation of $3,614,020.
David Roth is 57, he's been the Chief Medical Officer of Syros Pharmaceuticals since 2015. There are 12 older and 6 younger executives at Syros Pharmaceuticals. The oldest executive at Syros Pharmaceuticals Inc. is Phillip Sharp, 75, who is the Independent Director.
David's mailing address filed with the SEC is C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA, 02140.
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju, and Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Syros Pharmaceuticals executives and other stock owners filed with the SEC include: